Study guide
5.3 Biochemical Recurrence & Salvage Therapies
FEBU Part 1 Written European Board of Urology
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice
2 Chapter 2: Genitourinary Anatomy & Renal Physiology
2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance
3 Chapter 3: Urological Pharmacology & Diagnostic Imaging
3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine
4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification
4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging
5 Chapter 5: Prostate Cancer: Localized & Advanced Management
5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)
6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy
7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma
7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)
8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms
8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas
9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer
9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy
10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms
10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO
11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology
11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation
12 Chapter 12: Urolithiasis: Evaluation & Medical Management
12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy
13 Chapter 13: Endourology & Interventional Stone Management
13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety
14 Chapter 14: Infections, Andrology & Male Infertility
14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery
15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation
15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation
5.3 Biochemical Recurrence & Salvage Therapies
Key Takeaways Explain This Topic AI
A common post-RP BCR convention is PSA≥0.2 ng/mL with confirmation; EAU does not set one definitive relapse threshold and early SRT should not await an arbitrary PSA level. After RT, Phoenix failure is a rise ≥2 ng/mL above nadir.
PSMA-PET/CT is useful for BCR when it changes management; detection rises with PSA and is incomplete at low levels. A negative scan neither localizes disease to the bed nor justifies delaying otherwise indicated early SRT.
Early prostatic-bed SRT offers potential cure after RP and works better at lower PSA. Once SRT is chosen, give it promptly rather than waiting for a positive scan or threshold; EAU recommends at least 64 Gy.
GETUG-AFU16 tested six months of goserelin and improved progression-free survival, not demonstrated overall survival. RTOG9601 used 24 months of bicalutamide. Select adjunctive hormonal therapy and duration by recurrence risk, expected benefit and toxicity.
After RT, local salvage requires biopsy-proven recurrence, appropriate staging and careful selection in an experienced centre. Salvage RP has substantially greater urinary, rectal and sexual morbidity than primary RP; other modalities have different toxicity profiles.
Last updated: November 2026
5.3 Biochemical Recurrence & Salvage Therapies
Approximately 20% to 40% of men treated with radical prostatectomy (RP) or definitive radiation therapy (RT) develop a rising serum prostate-specific antigen (PSA) during follow-up, an oncological entity known as Biochemical Recurrence (BCR) . Biochemical recurrence precedes clinical radiological metastasis by an average of 5 to 8 years. For the European Board of Urology examination, candidates must master the distinct definitions of BCR following surgery versus radiation, understand modern molecular imaging restaging with PSMA-PET/CT, and evaluate evidence-based salvage therapeutic pathways.
1. Consensus Definitions of Biochemical Recurrence
Because the biological consequences of surgery and radiation differ fundamentally, their definitions of biochemical recurrence are distinct:
Post-Radical Prostatectomy BCR
Common Convention: PSA ≥0.2 ng/mL with a confirmatory elevation is widely used, including in AUA guidance. EAU notes that no single definitive post-RP relapse threshold can be specified; confirmed rises below this level may warrant early salvage assessment.
Pathophysiology: Following complete surgical removal of the prostate and seminal vesicles, healthy and malignant prostate epithelial cells are extirpated. PSA should become undetectable after recovery, usually by around two months, with the reported threshold depending on the assay. Persistent measurable PSA and a later rise after an undetectable nadir are distinct patterns. Repeat testing and the trend help interpretation; PSA alone does not locate the residual or recurrent tissue.
Post-Radiotherapy BCR (Phoenix Consensus Definition)
Definition: PSA nadir + 2.0 ng/mL (measured at any time following radiotherapy, regardless of whether the patient received concurrent androgen deprivation therapy).
Pathophysiology: Radiation therapy does not immediately ablate prostate tissue; rather, it induces mitotic cell death over months to years. Residual benign prostate parenchyma continues to secrete low levels of PSA, achieving a lowest post-treatment level known as the PSA nadir (which may take three years or longer). The Phoenix threshold defines biochemical failure and correlates with clinical outcomes; it does not by itself prove the site or histology of recurrence.
Note
The Post-Radiation PSA Bounce: In 10% to 30% of men—especially younger patients receiving brachytherapy—a benign self-limiting transient elevation in PSA occurs between 12 and 24 months post-radiotherapy, termed a PSA bounce . A bounce is usually modest and resolves spontaneously; assess serial measurements and clinical context rather than treating a single rise as proof of cancer progression. Treating a benign bounce prematurely with androgen deprivation therapy is a serious clinical error.
Risk Stratification of BCR: PSA Kinetics
Not all biochemical recurrences have the same prognosis. EAU uses different risk rules after surgery and radiotherapy:
After RP: Low risk means PSADT >1 year AND pathological GG<4 ; high risk means PSADT≤1 year OR pathological GG4–5 .
After RT: Low risk means interval to biochemical failure >18 months AND biopsy GG<4 ; high risk means interval≤18 months OR biopsy GG4–5 .
These groups guide counselling, monitoring and salvage decisions. There is no additional universal three-year cutoff in these definitions; high-risk recurrence requires timely individualized assessment rather than automatic treatment of every PSA rise.
2. Molecular Restaging: PSMA-PET/CT
Restaging can distinguish prostatic-bed, nodal and distant recurrence and change treatment fields. It is particularly important before invasive post-RT local salvage; post-RP bed SRT can still be indicated when microscopic recurrence is not visible.
Limitations of Conventional Imaging
Conventional imaging modalities—technetium-99m bone scintigraphy and contrast-enhanced CT of the abdomen and pelvis—have exceptionally low diagnostic yield in early biochemical recurrence. EAU reports a positive bone-scan probability <5% when PSA is <7 ng/mL in PSA-only recurrence after RP, and positive CT findings in only 11–14% of BCR patients. CT positivity in a cohort is not the same as sensitivity for normal-sized metastatic nodes.
Prostate-Specific Membrane Antigen (PSMA) PET/CT
PSMA is a transmembrane glycoprotein overexpressed up to 1,000-fold on prostate cancer cell membranes. Radiotracers targeting PSMA—such as 68Ga-PSMA-11 , 18F-DCFPyL , and 18F-PSMA-1007 —have revolutionized restaging. Prospective recurrent-disease studies show useful localization at PSA levels where conventional imaging is often negative. proPSMA studied initial high-risk staging , not BCR. Detection varies with PSA, tracer and population; a prospective 635-patient 68Ga-PSMA-11 study reported:
PSA <0.5 ng/mL: 38% positive.
PSA 0.5–<1.0: 57% .
PSA 1.0–<2.0: 84% .
PSA 2.0–<5.0: 86% , and ≥5.0: 97% .
These are study detection rates, not guaranteed sensitivity or proof that a negative scan excludes cancer.
Important
While PSMA-PET/CT is recommended for restaging BCR, early salvage radiation therapy post-RP must NOT be delayed to wait for a positive PSMA scan . If early SRT is clinically indicated for confirmed rising PSA, a negative scan should not delay it. PET can miss microscopic local, nodal or distant disease; negativity does not prove confinement to the bed. Low-risk BCR and limited life expectancy can instead support monitoring after an individual assessment.
3. Salvage Radiotherapy (SRT) Post-Prostatectomy
Salvage radiation therapy directed to the prostatic bed (with or without elective pelvic nodal irradiation) is the principal established treatment offering potential cure for a presumed local recurrence after prostatectomy.
Timing & Dose of Salvage Radiotherapy
Early Initiation: Lower pre-SRT PSA is associated with better control. Treat promptly once SRT is chosen, commonly before PSA exceeds 0.5 ng/mL , rather than waiting to reach a fixed threshold. Outcome also depends on grade, stage, PSA kinetics and treatment; there is no universal 10% loss of control for each 0.1 ng/mL increase.
Dose: EAU recommends at least 64 Gy to the bed, using modern conformal planning; doses around 64–70 Gy are used according to context. A mandatory minimum of 66–70 Gy is incorrect, and escalating dose can increase toxicity.
Addition of Concurrent Androgen Deprivation Therapy
The trials used different drugs, durations and endpoints:
GETUG-AFU16: SRT 66 Gy with or without six months of goserelin , for rising PSA after RP. Ten-year progression-free survival improved ( 64% versus 49% ); an overall-survival benefit was not demonstrated.
RTOG9601: SRT 64.8 Gy with or without 24 months of bicalutamide 150 mg/day . Overall survival improved in the trial population. A secondary analysis found no OS benefit and more other-cause mortality/toxicity at pre-SRT PSA ≤0.6 ng/mL ; this cannot be equated to six-month GnRH therapy.
Practice: EAU weakly recommends offering hormonal therapy with SRT. Discuss benefit, recurrence risk and adverse effects rather than requiring six months for everyone. Short courses of 4–6 months and longer courses in selected higher-risk patients have different evidence; RADICALS-HD found better MFS with 24 versus 6 months, with more prolonged toxicity. SRT alone remains appropriate for selected lower-risk patients.
Adjuvant vs Early Salvage Radiotherapy Controversy
Adverse pathology previously led to routine immediate ART. RADICALS-RT, RAVES and GETUG-AFU17 , combined in ARTISTIC , support PSA monitoring with an early-SRT policy for many men whose postoperative PSA is undetectable: five-year EFS was 89% with ART versus 88% with early-SRT policy , without significant evidence of benefit from ART, and only 39% of the salvage-policy group had needed RT at analysis. This is not proof of identical EFS/MFS for every subgroup. EAU still weakly recommends ART for pN0, GG4–5, pT3 with or without positive margins . Distinguish postoperative monitoring from AS for an untreated prostate.
4. Local Salvage Therapies Following Radiation Failure
When a patient develops biochemical recurrence following primary external beam radiotherapy or brachytherapy (Phoenix definition: nadir + 2.0 ng/mL), systemic treatment is not automatic. EAU advises against ADT for M0 recurrence with PSADT >12 months. For EMBARK-like high-risk BCR (conventionally M0, PSADT ≤9 months, PSA ≥1 ng/mL after RP or ≥2 ng/mL above the post-RT nadir), offer enzalutamide plus ADT when systemic salvage is appropriate. For a carefully selected subgroup with true isolated, histologically confirmed intraprostatic recurrence, local salvage therapy offers potential long-term cure.
Mandatory Pre-Requisite Staging for Local Salvage
Before contemplating invasive salvage local therapies, the clinician should:
Assess original stage/grade, PSA, recurrence interval, functional status and whether a curative salvage procedure is realistic; a longer interval is favourable rather than a universal mandatory >2–3-year requirement.
Confirm life expectancy >10 years and a low comorbidity burden.
Obtain histological confirmation of viable recurrence via transperineal/transrectal prostate re-biopsy .
Exclude visible nodal/distant metastases with appropriate staging, usually PSMA-PET/CT . Prostate MRI helps localize and target biopsy; negative imaging cannot exclude microscopic disease.
Local Salvage Modalities & Complication Profiles
Salvage Radical Prostatectomy (SRP): Complete excision of the irradiated prostate. Oncologically potent (5-year BCR-free survival 45–60%), but technically formidable due to radiation-induced endarteritis obliterans, marked tissue fibrosis, and obliteration of normal planes. Morbidity is severe: urinary incontinence rates of 40% to 70% , bladder neck contracture/stricture in 25% to 40%, rectal injury/rectourethral fistula in 5% to 10% , and near-universal erectile dysfunction.
Salvage Cryotherapy: Transperineal cryoablation using argon gas freezing cycles to achieve temperatures of -40°C. Lower operative morbidity than SRP, but causes urinary sloughing, urethral stricture (10–15%), and rectourethral fistula (1–3%).
Salvage Brachytherapy: Interstitial HDR or LDR brachytherapy delivers targeted focal or whole-gland re-irradiation. Produces 5-year biochemical control of 50–65%, with severe late grade 3 genitourinary/gastrointestinal toxicity of 5% to 15%.
Salvage HIFU: Acoustic thermal ablation can cause incontinence, obstruction and fistula. EAU restricts salvage HIFU and cryotherapy to selected patients in clinical trials or well-designed prospective cohorts; salvage RP, brachytherapy or SBRT also require careful selection in experienced centres.
5. Biochemical Recurrence & Salvage Decision Matrix
Setting Definition / Assessment Imaging Treatment Systemic Therapy / Caveat
Post-RP Common BCR convention: confirmed PSA≥0.2; EAU decisions also consider lower confirmed rises and risk PSMA-PET if it changes planning; negative PET does not delay indicated SRT Prompt bed SRT, ≥64 Gy , when selected Hormonal therapy individualized; six-month goserelin trial did not establish OS benefit
Post-RT Nadir+2 ng/mL ; biopsy proof before local salvage PSMA-PET/CT for salvage candidates; MRI for local assessment/biopsy Selected salvage RP, BT or SBRT in experienced centres; cryotherapy/HIFU in trials/prospective cohorts Monitor or use systemic therapy according to risk; no automatic ADT for slow M0 BCR; substantial modality-specific morbidity
Oligorecurrence Limited nodal/bone lesions after prior local treatment; distinguish from bed-only recurrence PSMA-PET/CT maps visible burden MDT such as SBRT in a clinical trial or well-designed prospective cohort STOMP/ORIOLE phase II results support delaying progression/ADT in selected patients, not proven OS benefit or one universal dose/systemic schedule